SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0944 1174 OR L773:1435 5922 "

Sökning: L773:0944 1174 OR L773:1435 5922

  • Resultat 1-10 av 18
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Bakke, Ingunn, et al. (författare)
  • Mucosal and faecal neutrophil gelatinase-associated lipocalin as potential biomarkers for collagenous colitis
  • 2021
  • Ingår i: Journal of gastroenterology. - : Springer Nature. - 0944-1174 .- 1435-5922. ; 56:10, s. 914-927
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Collagenous colitis (CC) is an inflammatory bowel disease where chronic diarrhoea is the main symptom. Diagnostic markers distinguishing between CC and other causes of chronic diarrhoea remain elusive. This study explores neutrophil gelatinase-associated lipocalin (NGAL) and its mRNA lipocalin2 (LCN2) as histological and faecal disease markers in CC. Methods NGAL/LCN2 were studied in colonic biopsies from CC patients before and during budesonide treatment using RNA sequencing (n = 9/group), in situ hybridization (ISH) (n = 13-22/group) and immunohistochemistry (IHC) (n = 14-25/group). Faecal samples from CC (n = 3-28/group), irritable bowel syndrome diarrhoea (IBS-D) (n = 14) and healthy controls (HC) (n = 15) were assayed for NGAL and calprotectin. Results NGAL/LCN2 protein and mRNA expression were upregulated in active CC vs HC, and vs paired samples of treated CC in clinical remission. IHC and ISH localized increased NGAL/LCN2 mainly to epithelium of active CC, compared to almost absence in HC and treated CC. In contrast, calprotectin was solely expressed in immune cells. Despite great individual differences, faecal NGAL was significantly increased in active CC compared to HC, IBS-D and treated CC and had high test sensitivity. Faecal calprotectin levels were variably increased in active CC, but the values remained below usual clinical cut-offs. Conclusion NGAL/LCN2 is upregulated in the epithelium of active CC and reduced during budesonide-induced clinical remission to the level of HC and IBD-S. This was reflected in NGAL faecal concentrations. We propose NGAL as an IHC marker for disease activity in CC and a potential faecal biomarker discriminating CC from HC and IBS-D.
  •  
2.
  • Bledsoe, Adam C., et al. (författare)
  • Mortality and cancer in eosinophilic gastrointestinal disorders distal to the esophagus : nationwide cohort study 1990-2017
  • 2022
  • Ingår i: Journal of gastroenterology. - : Springer. - 0944-1174 .- 1435-5922. ; 57, s. 735-747
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Eosinophilic gastrointestinal disorders (EGIDs) include inflammatory conditions with enteric infiltration of eosinophils and resulting symptoms. This study aims to examine a population-based sample of patients for prevalence, mortality, and cancer risk in EGIDs distal to the esophagus.Methods: Nationwide, population-based cohort study. EGID was identified through relevant biopsy codes from Sweden's all 28 pathology departments through the ESPRESSO cohort. Individuals with EGID were then matched to general population reference individuals with similar age and sex. Study participants were linked to Swedish healthcare registers. Through Cox regression, we calculated adjusted hazard ratios (aHRs) adjusting for sex, age, county, calendar period, and education.Results: In total, 2429 patients (56% female) were found to have EGID distal to the esophagus, representing a prevalence of about 1/4800 in the Swedish population. Mean age was 44 years with 11% children at the time of diagnosis. Mortality was increased 17% in patients with EGIDs compared to reference individuals (aHR = 1.17; 95%CI = 1.04-1.33). Excess mortality was seen in gastric and small bowel eosinophilic disease, but not colonic disease (aHR = 1.81; 95%CI = 1.32-2.48, aHR = 1.50; 95%CI = 1.18-1.89, and aHR = 0.99; 95%CI = 0.85-1.16, respectively). Cause specific mortality was driven by cancer-related death (aHR = 1.33; 95%CI = 1.05-1.69). However, this study failed to show an increase in incident cancers (aHR = 1.14; 95%CI = 0.96-1.35). Comparison of EGID individuals with their siblings yielded similar aHRs.Conclusions: This study found an increased risk of death in patients with EGIDs distal to the esophagus, with cancer death driving the increase. Proximal gut disease seems to confer the greatest risk. There was no increase in incident cancers.
  •  
3.
  • Brusselaers, Nele, et al. (författare)
  • Proton pump inhibitors and the risk of pancreatic cancer
  • 2021
  • Ingår i: Journal of gastroenterology. - : Springer Science and Business Media LLC. - 0944-1174 .- 1435-5922. ; 56:3, s. 295-296
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
4.
  • Gremel, Gabriela, et al. (författare)
  • The human gastrointestinal tract-specific transcriptome and proteome as defined by RNA sequencing and antibody-based profiling
  • 2015
  • Ingår i: Journal of gastroenterology. - : Springer. - 0944-1174 .- 1435-5922. ; 50:1, s. 46-57
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: The gastrointestinal tract (GIT) is subdivided into different anatomical organs with many shared functions and characteristics, but also distinct differences. We have combined a genome-wide transcriptomics analysis with immunohistochemistry-based protein profiling to describe the gene and protein expression patterns that define the human GIT. METHODS: RNA sequencing data derived from stomach, duodenum, jejunum/ileum and colon specimens were compared to gene expression levels in 23 other normal human tissues analysed with the same method. Protein profiling based on immunohistochemistry and tissue microarrays was used to sub-localize the corresponding proteins with GIT-specific expression into sub-cellular compartments and cell types. RESULTS: Approximately 75% of all human protein-coding genes were expressed in at least one of the GIT tissues. Only 51 genes showed enriched expression in either one of the GIT tissues and an additional 83 genes were enriched in two or more GIT tissues. The list of GIT-enriched genes with validated protein expression patterns included various well-known but also previously uncharacterised or poorly studied genes. For instance, the colon-enriched expression of NXPE family member 1 (NXPE1) was established, while NLR family, pyrin domain-containing 6 (NLRP6) expression was primarily found in the human small intestine. CONCLUSIONS: We have applied a genome-wide analysis based on transcriptomics and antibody-based protein profiling to identify genes that are expressed in a specific manner within the human GIT. These genes and proteins constitute important starting points for an improved understanding of the normal function and the different states of disease associated with the GIT.
  •  
5.
  •  
6.
  • Inoue T, T, et al. (författare)
  • Autofluorescence imaging videoendoscopy in the diagnosis of chronic atrophic fundal gastritis
  • 2010
  • Ingår i: Journal of Gastroenterology. - : Springer Science and Business Media LLC. - 0944-1174 .- 1435-5922. ; 45:1, s. 45-51
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose: Diagnosis of chronic atrophic fundal gastritis (CAFG) is important to understand the pathogenesis of gastric diseases and assess the risk of gastric cancer. Autofluorescence imaging videoendoscopy (AFI) may enable the detection of mucosal features not apparent by conventional white-light endoscopy. The purpose of this study was to estimate the diagnostic ability of AFI in CAFG. Methods: A total of 77 patients were enrolled. Images of the gastric body in AFI and white-light mode were taken to assess the extent of gastritis, and biopsies were taken from green (n = 119) and purple (n = 146) mucosa in AFI images. The diagnostic accuracy of green mucosa for CAFG was investigated according to the Sydney system. Results: In per-patient analysis, the accuracy of green mucosa in patients with activity, inflammation, atrophy and intestinal metaplasia was 64, 93, 88 and 81%, respectively. In per-biopsy analysis, the accuracy for activity, inflammation, atrophy and intestinal metaplasia was 55, 62, 76 and 76%, respectively. Green areas in the gastric body exhibited more inflammation (p\0.001), atrophy (p\0.001) and intestinal metaplasia (p\0.001), whereas purple areas rarely contained atrophy or intestinal metaplasia. The kappa statistics for inter- and intra-observer agreement of AFI on assessing the extent of CAFG were 0.66 and 0.47, while those for white-light endoscopy were 0.56 and 0.39. Conclusions: AFI could diagnose the extent of CAFG as a green area in the gastric body, with higher reproducibility compared with white-light endoscopy. Therefore, AFI may be a useful adjunct to endoscopy to identify patients at high risk of developing gastric cancer.
  •  
7.
  •  
8.
  • Johansson, Johan, et al. (författare)
  • Pancreatic acinar metaplasia in the distal oesophagus and the gastric cardia: prevalence, predictors and relation to GORD
  • 2010
  • Ingår i: JOURNAL OF GASTROENTEROLOGY. - : Springer Science and Business Media LLC. - 0944-1174 .- 1435-5922. ; 45:3, s. 291-299
  • Tidskriftsartikel (refereegranskat)abstract
    • The nature of pancreatic acinar metaplasia (PAM) in the gastro-oesophageal junction (GOJ) remains obscure. We aimed to estimate its prevalence and investigate into its risk factors in a population-based series of first-time endoscopy patients. We investigated consecutive patients, endoscoped for the first time, representing defined catchment area populations. Biopsies were taken immediately below the GOJ and from the distal oesophagus. Endoscopy room-based cross-sectional clinical data were supplemented with exposure data from 160 population controls. Associations, expressed as odds ratios (OR), were modelled with multivariable logistic regression. A subsample of 26 patients underwent oesophageal pH monitoring. Among 644 patients (mean age 53 years, 43% men), PAM was found in 121 patients (19%), exclusively above the GOJ in 40 (6%), below GOJ in 67 (10%), and both above and below GOJ in 14 (2%). PAM exclusively above the GOJ and PAM exclusively below the GOJ were both borderline associated with age (2% increase in prevalence per year). PAM exclusively above the GOJ was significantly associated with female gender (OR 2.8, 95% CI 1.3-6.3) and presence of Helicobacter pylori immediately below the GOJ (OR 2.6, 95% CI 1.3-5.4). Out of 21 patients with Barretts oesophagus (BO), 8 (38%) had PAM above the GOJ. The mean value for percentage time with oesophageal pH andlt; 4.0 was 7.3% (95% CI 4.3-10.2%) among patients who had PAM above the GOJ (reference value 3.4%). Pancreatic acinar metaplasia might be an age-dependent lesion, associated with H. pylori, female gender and gastro-oesophageal reflux if located above the GOJ.
  •  
9.
  •  
10.
  • Ludvigsson, Jonas F., et al. (författare)
  • Risk of lymphoproliferative malignancy in celiac patients with a family history of lymphoproliferative malignancy
  • 2013
  • Ingår i: Journal of gastroenterology. - : Springer Science and Business Media LLC. - 0944-1174 .- 1435-5922. ; 48:12, s. 1324-1331
  • Tidskriftsartikel (refereegranskat)abstract
    • Individuals with celiac disease (CD) are at increased risk of lymphoproliferative malignancy (LPM). We examined if a family history of LPM or any cancer influenced the risk of LPM in individuals with CD. We identified 28,996 individuals with biopsy-verified CD (equal to villous atrophy, Marsh histopathology stage 3), of whom 616 had family history of LPM. Cox regression then estimated hazard ratios (HRs) for LPM in these 616 compared with two control groups. We also examined the risk of LPM in CD individuals with a family history of any cancer (n = 8,439). During follow-up, 2/616 CD individuals with a family history of LPM, and 235/28,380 CD individuals without a family history of LPM developed LPM themselves. CD individuals with a family history of LPM were not at increased risk of LPM compared to general population controls (HR = 1.18; 95 % CI = 0.27-5.10), or compared to CD individuals without a family history of LPM (adjusted HR = 0.31; 95 % CI = 0.08-1.23). We found no increased risk of LPM in CD individuals with a family history of any cancer. This study found no evidence that a family history of LPM or any cancer increases the risk of future LPM in individuals with CD. Despite the large number of study participants, this study is nevertheless limited by few positive events due to a low absolute risk of LPM even in individuals with CD.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 18
Typ av publikation
tidskriftsartikel (18)
Typ av innehåll
refereegranskat (16)
övrigt vetenskapligt/konstnärligt (2)
Författare/redaktör
Johansson, Karl-Erik (1)
Piitulainen, Eeva (1)
Jacobsson, H (1)
Granath, Fredrik (1)
Pontén, Fredrik (1)
Chang-Claude, Jenny (1)
visa fler...
Lagergren, J (1)
Uhlén, Mathias (1)
Engstrand, Lars (1)
Fagerberg, Linn (1)
Brudin, Lars (1)
Engstrom, M (1)
Ekbom, Anders (1)
Nyrén, Olof (1)
Carbone, F (1)
Berndt, Sonja I (1)
Brenner, Hermann (1)
Thibodeau, Stephen N (1)
Tomita, Y. (1)
Li, Yuan (1)
Lofberg, R (1)
Ulfgren, AK (1)
Lin, Yi (1)
Qu, Conghui (1)
Buchanan, Daniel D. (1)
Chan, Andrew T. (1)
Gunter, Marc J. (1)
Harlid, Sophia, 1978 ... (1)
Hidaka, Akihisa (1)
Harrison, Tabitha A. (1)
Hoffmeister, Michael (1)
Jenkins, Mark A. (1)
Obón-Santacana, Mire ... (1)
Moreno, Victor (1)
Newcomb, Polly A. (1)
Ogino, Shuji (1)
Pai, Rish K. (1)
Potter, John D. (1)
Sakoda, Lori C. (1)
Schoen, Robert E. (1)
Slattery, Martha L. (1)
van Guelpen, Bethany (1)
Hsu, Li (1)
Peters, Ulrike (1)
Campbell, Peter T. (1)
Cross, Amanda J. (1)
Patrone, C (1)
Milne, Roger L. (1)
Ludvigsson, Jonas F. ... (1)
Ye, Weimin (1)
visa färre...
Lärosäte
Karolinska Institutet (9)
Linköpings universitet (4)
Uppsala universitet (3)
Örebro universitet (3)
Umeå universitet (2)
Lunds universitet (2)
visa fler...
Göteborgs universitet (1)
Kungliga Tekniska Högskolan (1)
visa färre...
Språk
Engelska (18)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (14)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy